Pancreatic Cancer

Pancreatic cancer develops in the pancreas, an organ located deep in the abdomen behind the stomach that produces digestive enzymes and hormones including insulin. Approximately 496,000 new cases are diagnosed worldwide each year. The most common type (about 90% of cases) is pancreatic ductal adenocarcinoma, which arises from the cells lining the ducts that carry digestive enzymes. This cancer develops when cells in the pancreas acquire genetic mutations—commonly in genes called KRAS, TP53, SMAD4, and CDKN2A—that cause uncontrolled growth. A characteristic feature is the dense, fibrous tissue (called desmoplastic stroma) that surrounds pancreatic tumors, consisting of supportive cells, collagen, and blood vessels that create a physical barrier protecting cancer cells from immune attack and limiting drug penetration. Risk factors include smoking, obesity, diabetes, chronic pancreatitis, family history, and inherited genetic mutations (including BRCA1/BRCA2, Lynch syndrome, and others). The pancreas's deep location in the abdomen and the vague, non-specific symptoms—including abdominal or back pain, weight loss, jaundice (yellowing of skin and eyes), digestive problems, and new-onset diabetes—mean the disease is often advanced by the time it's discovered. About 80-85% of patients have disease that has spread locally or to distant organs at diagnosis, making treatment more challenging.

Surgery offers the only potential for cure and involves complex operations (Whipple procedure for tumors in the pancreas head, or distal pancreatectomy for body/tail tumors) that require specialized surgical expertise. Only about 15-20% of patients have surgically removable (resectable) tumors at diagnosis. After surgery, adjuvant chemotherapy—typically FOLFIRINOX (a four-drug combination) or gemcitabine plus capecitabine—significantly reduces recurrence risk and extends survival. For locally advanced disease that isn't surgically removable or for metastatic disease, chemotherapy is the primary treatment. FOLFIRINOX offers the strongest anti-tumor effects but requires good overall health to tolerate, while gemcitabine combined with nab-paclitaxel provides another effective option with different side effects. Some patients receive neoadjuvant therapy (chemotherapy and sometimes radiation before surgery) to shrink borderline resectable tumors and improve surgical outcomes. A significant advance was the approval of PARP inhibitors (olaparib, then rucaparib) for patients whose tumors have BRCA1, BRCA2, or related DNA repair gene mutations—these pills block cancer cells' ability to repair DNA damage and can provide meaningful disease control. Immunotherapy has been approved for the small subset (about 1-2%) of pancreatic cancers with mismatch repair deficiency or high microsatellite instability. Pain management, nutritional support (including pancreatic enzymes to aid digestion), and treatments for diabetes are important components of care. Five-year survival rates have gradually improved from around 5% in the 1990s to approximately 12% today, reflecting incremental advances in surgery, chemotherapy, and supportive care.

Early detection remains extremely difficult—the pancreas's deep location makes physical examination ineffective, and symptoms typically don't appear until disease is advanced. No effective screening test exists for the general population, though high-risk individuals with strong family histories or genetic mutations may undergo surveillance. The dense fibrous tissue surrounding pancreatic tumors creates physical and chemical barriers that prevent chemotherapy and immune cells from reaching cancer cells effectively, limiting treatment effectiveness. Most pancreatic cancers don't respond to immunotherapy approaches that have transformed other cancers, and understanding why the immune system can't effectively attack these tumors remains an active research focus. Resistance to chemotherapy develops through various mechanisms, and options become limited after disease progresses through first and second-line treatments. Treatment side effects including fatigue, neuropathy (nerve damage), digestive problems, and nutritional challenges affect quality of life. Many patients experience significant weight loss and wasting that's difficult to reverse even with nutritional support. Better biomarkers to predict which treatments will work for individual patients would enable more personalized therapy selection. The approximately 10% of patients with inherited genetic mutations benefit from PARP inhibitors, but the remaining 90% lack targeted therapies addressing their tumors' specific drivers. Surgical complications can be serious, and recovery requires weeks to months, during which micrometastases may continue growing if present.

Multiple strategies to overcome the fibrous tumor barrier are in clinical trials, including drugs that break down collagen and supportive cells (like PEGPH20 and other stromal-targeting agents) to improve chemotherapy penetration. Novel chemotherapy combinations and delivery methods are being tested, including nanoparticle formulations designed to concentrate drugs at tumor sites. Immunotherapy combination approaches are in Phase 2 and Phase 3 trials, testing checkpoint inhibitors paired with chemotherapy, vaccines, or drugs that modify the tumor microenvironment to make it more hospitable to immune attack. Therapeutic cancer vaccines targeting mutated KRAS—the most common genetic alteration in pancreatic cancer—are in trials, designed to train the immune system to recognize and attack cells carrying this mutation. For patients with BRCA and related mutations, trials are evaluating whether combining PARP inhibitors with chemotherapy or immunotherapy improves outcomes beyond PARP inhibitors alone. Radioligand therapies targeting molecules on pancreatic cancer cells are being developed, similar to approaches successful in other cancers. Oncolytic viruses engineered to selectively infect and kill cancer cells while stimulating immune responses are in testing. Researchers are investigating whether adding targeted drugs that inhibit specific signaling pathways (like KRAS inhibitors for specific KRAS mutations) to chemotherapy improves outcomes. Neoadjuvant therapy approaches using more intensive treatment combinations before surgery are being evaluated to increase the percentage of patients who can undergo potentially curative operations.

KRAS G12D and G12V inhibitors—targeting the most common KRAS mutations in pancreatic cancer—are advancing from laboratory studies toward clinical testing, potentially addressing the driver mutation in the majority of cases. Scientists are developing next-generation immunotherapies including personalized cancer vaccines, engineered T cells (CAR-T and TCR-T therapies), and novel ways to activate the immune system against pancreatic tumors despite their immunosuppressive environment. Researchers are investigating the tumor microenvironment comprehensively—the supportive cells, blood vessels, nerve fibers, and immune cells surrounding cancer—to identify combination approaches that simultaneously attack cancer cells and dismantle their protective environment. Organoid technology—growing miniature patient tumors in the laboratory from biopsy or surgical samples—enables testing multiple treatments to identify the most effective option before starting therapy and is being used for drug discovery. Liquid biopsies detecting tumor DNA in blood and pancreatic juice are being refined for earlier cancer detection in high-risk individuals, monitoring treatment response, and detecting recurrence before it's visible on imaging. Artificial intelligence is analyzing genetic, molecular, and imaging data to predict treatment responses and identify new therapeutic targets from massive datasets. Scientists are exploring metabolic vulnerabilities—ways pancreatic cancer cells produce energy and building blocks differently than normal cells—to develop drugs that exploit these differences. Researchers are investigating whether gut bacteria influence pancreatic cancer development and treatment response, with some evidence suggesting microbiome composition affects chemotherapy effectiveness. Nanotechnology approaches are being designed to overcome the dense stroma barrier and deliver treatments directly to cancer cells. Gene therapy and RNA-based therapeutics targeting cancer-causing mutations are in development. Scientists are studying why pancreatic cancer is so resistant to immunotherapy, investigating whether targeting specific immune-suppressing mechanisms or combining multiple immune-activating approaches could overcome this resistance.